Litcius/Paper detail

MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists

Michael Cooreman, Luisa Vonghia, Sven Francque

2024Diabetes Research and Clinical Practice46 citationsDOI

Topics & Concepts

Insulin resistanceRosiglitazonePeroxisome proliferator-activated receptorInternal medicineEndocrinologyMedicineType 2 diabetesPPAR agonistGlucose homeostasisAdipose tissueLipid metabolismFatty liverLipotoxicityMetabolic syndromeInsulinDiabetes mellitusReceptorDiseaseLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated ReceptorsMetabolism, Diabetes, and Cancer
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists | Litcius